Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Finerenone

Next Previous
Drug Profile

Finerenone

Alternative Names: BAY-94-8862

Latest Information Update: 26 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Amides; Heart failure therapies; Naphthyridines; Nitriles; Small molecules
  • Mechanism of Action Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic heart failure; Diabetic nephropathies
  • Phase I Renal failure

Most Recent Events

  • 18 Jun 2019 Bayer terminates a phase III FINESSE-HF trial in Chronic heart failure in Sweden, Ireland, Germany, in the UK, Austria, Hungary, Netherlands, Spain, Poland and Greece (PO) (EudraCT2015-002168-17)
  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-heart-failure(In volunteers) in Germany (PO, Immediate release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top